---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-024502"
form_type: "8-K"
ticker: "IRD"
cik: "0001228627"
company_name: "Opus Genetics, Inc."
filed_at: "2023-05-15T23:59:59+00:00"
generated_at: "2026-06-15T00:43:10.148496+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Ocuphire reports Q1 2023 cash $39M; Nyxol PDUFA Sept 28; net loss $5.8M

## Summary
- Cash and cash equivalents of $39.0M, no debt; operations funded into 2025.
- Revenue $1.7M from Nyxol license reimbursement (vs $0 prior year); net loss $5.8M ($0.28/sh) vs $6.6M ($0.35).
- PDUFA date for Nyxol in RM set for Sept 28, 2023; approval triggers $10M milestone payment.
- End-of-Phase 2 meeting with FDA for APX3330 in DR expected in 2H 2023.
- Topline results for Nyxol in presbyopia (VEGA-2) expected in late 2023.

## SEC filing metadata
- accession: 0001140361-23-024502
- form_type: 8-K
- ticker: IRD
- cik: 0001228627
- company_name: Opus Genetics, Inc.
- filed_at: 2023-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1228627/000114036123024502/0001140361-23-024502-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1228627/000114036123024502/brhc20052778_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-024502
- JSON: https://secwatch.observer/filing/0001140361-23-024502.json
- Plain text: https://secwatch.observer/filing/0001140361-23-024502.txt

## Key facts
- Earnings Releases
  Opus Genetics, Inc. reported first quarter ended March 31, 2023 results: revenue 1.7 million, net income -5.8 million, EPS -0.28.
  - Period: first quarter ended March 31, 2023
  - Revenue: 1.7 million
  - Net income: -5.8 million
  - EPS: -0.28
  - Result: reported results
  source text: has no debt. Based on current projections, management believes the present cash on hand will be sufficient to fund operations into 2025. License and collaborations revenue was $1.7 million for the three months ended March 31, 2023. There was no revenue recorded in the three months ended March 31, 2022. Revenue during the first quarter of 2023 was derived from the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1228627/000114036123024502/0001140361-23-024502-index.htm
- Earnings Releases
  Opus Genetics, Inc. reported first quarter ended March 31, 2023 results: revenue 1.7 million, net income -5.8 million, EPS -0.28.
  - Period: first quarter ended March 31, 2023
  - Revenue: 1.7 million
  - Net income: -5.8 million
  - EPS: -0.28
  - Result: reported results
  source text: License and collaborations revenue was $1.7 million for the three months ended March 31, 2023. There was no revenue recorded in the three months ended March 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1228627/000114036123024502/0001140361-23-024502-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.